Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26996818 | 0.88 | OPRM1 (0.37) | OPRM1OPRK1PRCPSIGMAR1KDM1A | |
| SCHEMBL26269491 | 0.87 | CRHR1 (0.38) | CRHR1OPRM1OPRK1PRCPSIGMAR1 | |
| SCHEMBL26996825 | 0.87 | BIRC2 (0.37) | OPRM1OPRK1PRCPSIGMAR1KDM1A | |
| SCHEMBL18289331 | 0.85 | NTRK1 (0.39) | OPRM1OPRK1PRCPSIGMAR1 | |
| SCHEMBL22808490 | 0.82 | OPRM1 (0.33) | OPRM1OPRK1PRCPSIGMAR1 | |
| SCHEMBL22456647 | 0.81 | BIRC2 (0.35) | OPRM1OPRK1PRCPSIGMAR1 | |
| SCHEMBL26996828 | 0.81 | OPRM1 (0.36) | OPRM1OPRK1PRCPSIGMAR1 | |
| SCHEMBL23979191 | 0.80 | CRHR1 (0.42) | CRHR1OPRM1PRCPMAOBMAOA | |
| SCHEMBL23978833 | 0.79 | CRHR1 (0.43) | CRHR1MAOBMAOAKDM1A | |
| SCHEMBL10283336 | 0.78 | OPRM1 (0.41) | OPRM1OPRK1PRCPSIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| WO-2021222614-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | CRHR1 4419/4885OPRM1 4721/4885OPRK1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.